FACTOR VII

Written By:Sakshi Anil MoreB. Pharm Reviewed By:Dr. Tejashwin AdigaMBBS

Last updated on 26 Sep 2026 | 08:43 AM (IST)

FACTOR VII

Background and Date of approval FACTOR VII

Factor VII was initially approved by the United States Food and Drug Administration (FDA) on March 25, 1999.

Uses of FACTOR VII

Factor VII is primarily used to treat bleeding disorders. Its key applications include managing bleeding episodes in hemophilia patients with inhibitors, addressing congenital Factor VII deficiency, controlling bleeding during surgery and trauma, managing acquired Factor VII deficiency associated with certain medical conditions, and occasionally, as part of treatment strategies for intracranial hemorrhage.

How is FACTOR VII administered?

Factor VII concentrates are typically administered intravenously (IV) to individuals with bleeding disorders. A healthcare provider should determine the specific dosing and administration details based on the patient's condition and needs.

Side Effects of FACTOR VII

Factor VII can have several potential side effects, ranging from common to serious. Common side effects may include fever, headache, nausea, vomiting, and injection site reactions. However, more serious side effects can occur, including thromboembolic events (such as deep vein thrombosis and pulmonary embolism), hypersensitivity reactions (anaphylaxis), arterial thrombosis, disseminated intravascular coagulation (DIC), and bleeding.

Warnings

Factor VII is associated with an increased risk of thromboembolic events, including deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis. Severe allergic reactions (anaphylaxis) to this medication have been reported. When using this for intracranial hemorrhage, there is a concern of exacerbating thrombosis within the brain's blood vessels.

Precautions

Patients with a history of thromboembolic events, underlying cardiovascular conditions, or other risk factors for clot formation should be carefully assessed before using Factor VII. Patients should be monitored for signs of hypersensitivity during and after administration. Immediate treatment should be available in case of an allergic reaction. Neurological monitoring and consultation with a neurologist or neurosurgeon may be done.

Word of Advice

Watch for allergic reactions and the risk of clotting events after taking Factor VII, and closely monitor the medication's dosage and its effects on blood clotting. Special care is needed when using this medication in patients with liver problems, kidney issues, heart conditions, or a history of blood clots. Extra attention should be given to children and older adults. It's important to use the medication correctly, store it properly, and educate patients on its use. Emergency plans should be in place for unexpected issues. Also, consider factors like the development of antibodies and genetic variations in patients. Each patient is unique, so there should be communication between the healthcare provider and the patient to achieve the best results.

Frequently Asked Questions

Q1.

What should I do in an emergency or if I experience adverse effects while using Factor VII?

In emergencies or if you experience severe adverse effects, seek immediate medical attention. Have an emergency plan in place for unexpected issues while using this medication.

Q2.

Can Factor VII be self-administered at home?

Some patients with bleeding disorders may be trained to self-administer Factor VII concentrates at home. However, this depends on individual circumstances and should be supervised by healthcare professionals.

Q3.

Are there any dietary restrictions while using Factor VII?

There are typically no specific dietary restrictions associated with Factor VII concentrates. However, maintaining a balanced diet and staying well-hydrated can support overall health.

Q4.

Is genetic testing necessary before using Factor VII?

In some cases, genetic testing may be considered to identify genetic variations that could impact the patient's response to treatment. However, it is only sometimes required for some patients.

Q5.

Is Factor VII therapy lifelong for individuals with bleeding disorders?

The duration of Factor VII concentrate therapy varies depending on the underlying bleeding disorder and the patient's response to treatment. Some individuals may require lifelong treatment, while others may use it as needed.

References

Novo Nordisk A/S, Electronic medicines compendium (EMC), [Revised on 13 Jun 2023] [ Accessed on 2nd September 2023], https://www.medicines.org.uk/emc/files/pil.7927.pdf
LFB S.A. Puteaux, US Food and Drug Administration, [Revised on Dec 2022] [ Accessed on 2nd September 2023],https://www.fda.gov/media/136610/download
Katherine F Croom, Paul L McCormack; Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders; BioDrugs; Published on 2008; Accessed on 02/09/2023; https://pubmed.ncbi.nlm.nih.gov/18345709/

Disclaimer

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.

;